Latest Trials Latest NewsFAQ

BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Phase 1

Completed

Conditions: Metastatic Melanoma
Metastatic Castration-resistant Prostrate Cancer
Renal Cell Carcinoma
Non-small Cell Lung Cancer

Interventions: Biological: BMS-936558 (MDX-1106)

First Posted Date: 2008-08-08

Last Posted Date: 2021-12-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 395

Registration Number: NCT00730639

Locations: 🇺🇸
Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 10 locations

Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

First Posted Date: 2008-08-08

Last Posted Date: 2010-04-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 92

Registration Number: NCT00729950

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Piedmont Oncology Specialists, Charlotte, North Carolina, United States

and more 1 locations

Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma

Phase 1

Withdrawn

Conditions: Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.

Interventions: Biological: MDX-1411

First Posted Date: 2008-08-08

Last Posted Date: 2010-04-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 34

Registration Number: NCT00730652

Multiple Ascending Dose (MDX1105-01)

Phase 1

Completed

Conditions: Cancer, Multiple Indications

Interventions: Biological: Anti-PDL-1 antibody

First Posted Date: 2008-08-07

Last Posted Date: 2015-09-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 281

Registration Number: NCT00729664

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
The University Of Texas, Houston, Texas, United States

and more 8 locations

Drug Interaction Study With a Potential Alzheimer's Disease Compound

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)
Drug: BMS-708163
Drug: BMS-708163 + Cooperstown Cocktail

First Posted Date: 2008-08-01

Last Posted Date: 2008-11-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT00726726

Locations: 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: BMS-650032
Drug: Placebo

First Posted Date: 2008-07-25

Last Posted Date: 2011-06-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT00722358

Locations: 🇺🇸
Advanced Clinical Res Inst, Anaheim, California, United States
🇵🇷
Local Institution, Santurce, Puerto Rico
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

and more 2 locations

A Belatacept Compassionate Use Study for Patients With a Kidney Transplant

Conditions: Renal Transplantation

First Posted Date: 2008-07-21

Last Posted Date: 2021-11-23

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00719225

Locations: 🇺🇸
Scripps Green Hospital, La Jolla, California, United States
🇺🇸
Tulane Abdominal Transplant Institute, New Orleans, Louisiana, United States
🇺🇸
Office Of Dr. Allan Kirk, Atlanta, Georgia, United States

and more 4 locations

Suboptimal Responders to Adefovir Switching to Entecavir

Phase 4

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Adefovir/Entecavir
Drug: Entecavir

First Posted Date: 2008-07-21

Last Posted Date: 2013-02-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 228

Registration Number: NCT00718887

Locations: 🇨🇳
Local Institution, Shanghai, Shanghai, China

Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: BMS-767778 or Placebo

First Posted Date: 2008-07-01

Last Posted Date: 2009-02-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 120

Registration Number: NCT00707590

Locations: 🇨🇦
Local Institution, Quebec, Canada

Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg

Phase 1

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Placebo
Drug: Abatacept

First Posted Date: 2008-06-26

Last Posted Date: 2013-07-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 13

Registration Number: NCT00705367

Locations: 🇨🇳
Local Institution, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy